Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EBITDA (2024 - 2025)

Historic EBITDA for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $2.4 million.

  • Neuphoria Therapeutics' EBITDA fell 2466.47% to $2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.2 million, marking a year-over-year change of. This contributed to the annual value of -$201103.0 for FY2025, which is 9869.81% up from last year.
  • According to the latest figures from Q4 2025, Neuphoria Therapeutics' EBITDA is $2.4 million, which was down 2466.47% from -$9.9 million recorded in Q3 2025.
  • Over the past 5 years, Neuphoria Therapeutics' EBITDA peaked at $11.1 million during Q1 2025, and registered a low of -$9.9 million during Q3 2025.